TAK-659 is a novel FLT3 inhibitor in the initial trial stages for the treatment of acute myeloid leukemia (AML). Interestingly, TAK-659 also inhibits SYK, a target that is more common in the treatment of B-cell malignancies. In this interview, Mark Levis, MD, PhD, of Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses the pharmacokinetics and promising preliminary results of the Phase I trial of this agent (NCT02323113) in patients with relapsed or refractory AML. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Combining FLT3 and SYK inhibition for AML
